Research

Effects of Folate Conversion Problems (MTHFR Polymorphisms)

What Is a Folate Conversion Problem?

The MTHFR gene (especially the C677T and A1298C variants) controls an enzyme that converts folate into its active form, 5-methyltetrahydrofolate (5-MTHF). When this enzyme doesn't work efficiently, the body can't use folate properly — even if dietary intake is adequate. This leads to a functional folate deficiency and elevated homocysteine levels (hyperhomocysteinemia).

Neuropsychiatric Effects

Active folate is essential for producing S-adenosylmethionine (SAM), the body's main methyl donor, which is required to make serotonin, dopamine, and norepinephrine. Studies of cerebrospinal fluid in folate-deficient patients show significantly reduced levels of serotonin and dopamine metabolites, directly linking impaired folate metabolism to neurotransmitter deficiency.

Meta-analyses show the MTHFR 677TT genotype is associated with increased risk of major depression (OR 1.36), bipolar disorder (OR 1.82), and schizophrenia (OR 1.44). In rare, severe cases of MTHFR deficiency, epileptic encephalopathy, psychomotor delays, progressive neurologic deterioration, and demyelinating myelopathy can occur.

Cardiovascular Effects

Elevated homocysteine from impaired folate conversion promotes endothelial dysfunction, oxidative stress, and hypercoagulability. A 5 μmol/L increase in homocysteine is associated with an OR of 1.59 for ischemic stroke, with the MTHFR 677TT genotype specifically linked to small vessel stroke in both East Asian and European populations. Meta-analyses also show a modest but significant increased risk of coronary heart disease (OR ~1.16–1.21) in 677TT homozygotes. The 677TT genotype is convincingly linked to elevated blood pressure, which responds to riboflavin (vitamin B2) supplementation specifically in TT carriers.

Reproductive and Developmental Effects

Impaired folate conversion during the periconceptional period increases the risk of neural tube defects (spina bifida, anencephaly) — up to 70% of which are preventable with adequate folic acid supplementation. It is also associated with recurrent pregnancy loss, preeclampsia, preterm birth, and low birth weight. The USPSTF recommends 0.4–0.8 mg of folic acid daily for all persons planning or capable of pregnancy.

Other Associated Conditions

MTHFR polymorphisms have been linked to increased susceptibility to certain cancers (colorectal, breast, prostate), autoimmune diseases, cognitive decline, and metabolic disorders such as non-alcoholic fatty liver disease, though the strength of evidence varies.

Management

- L-methylfolate (5-MTHF) bypasses the impaired MTHFR enzyme and is the preferred supplement for individuals with MTHFR polymorphisms. A meta-analysis found adjunctive L-methylfolate modestly improved antidepressant response in major depression (RR 1.25).

- Folic acid (0.8 mg/day) reduced ischemic stroke risk by 24% in hypertensive adults in the CSPPT trial.

- Riboflavin (vitamin B2) is the cofactor for MTHFR and has shown blood pressure–lowering effects specifically in TT genotype carriers.

- Vitamin B12 and B6 support homocysteine remethylation and transsulfuration pathways.

Notably, routine MTHFR genetic testing is generally not recommended by most guidelines, as the treatment for elevated homocysteine (B-vitamin supplementation) is the same regardless of genotype.

References:

1. Methylphenidate Hydrochloride. FDA Drug Label.Food and Drug Administration. Updated date: 2025-03-12.

2.Headache in ADHD as Comorbidity and a Side Effect of Medications: A Systematic Review and Meta-Analysis. Psychological Medicine. 2022. Pan PY, Jonsson U, Şahpazoğlu Çakmak SS, et al.SR

3. MTHFR Gene Polymorphisms: A Single Gene With Wide-Ranging Clinical Implications-a Review. Genes. 2025. Araszkiewicz AF, Jańczak K, Wójcik P, et al.Review

4. MTHFR Polymorphisms, Homocysteine Elevation, and Ischemic Stroke Susceptibility in East Asian and European Populations. Neurology. 2025. Wang M, Daghlas I, Zhang Z, Gill D, Liu D.

5. Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues. The Journal of Clinical Psychiatry. 2010. Fava M, Mischoulon D.Review

6.Homocysteine, Folate, Methylation, and Monoamine Metabolism in Depression. Journal of Neurology, Neurosurgery, and Psychiatry. 2000. Bottiglieri T, Laundy M, Crellin R, et al.Clinical Trial

7. Linking genetics to epigenetics: The role of folate and folate‐related pathways in neurodevelopmental disorders. Clinical Genetics. 2019. Lintas C.Review

8. Association of Cerebrospinal Fluid Deficiency of 5-Methyltetrahydrofolate, but Not S-Adenosylmethionine, With Reduced Concentrations of the Acid Metabolites of 5-Hydroxytryptamine and Dopamine. Clinical Science. 1994. Surtees R, Heales S, Bowron A.

9. Methylenetetrahydrofolate Reductase (MTHFR) Genetic Polymorphisms and Psychiatric Disorders: A HuGE Review. American Journal of Epidemiology. 2007. Gilbody S, Lewis S, Lightfoot T.SR

10. Pearls & Oy-Sters: Familial Epileptic Encephalopathy Due to Methylenetetrahydrofolate Reductase Deficiency. Neurology. 2014. Cappuccio G, Cozzolino C, Frisso G, et al.Case

11.Folate, Vitamin B12, and Neuropsychiatric Disorders. Nutrition Reviews. 1996. Bottiglieri T.Review

12. Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence. The Journal of the American Medical Association. 2003. Hackam DG, Anand SS.Review

13. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/­American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; And the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology Affirms the Value of This Guideline. Stroke. 2006. Goldstein LB, Adams R, Alberts MJ, et al.Guideline

14.MTHFR 677TT Genotype and Disease Risk: Is There a Modulating Role for B-Vitamins?.

The Proceedings of the Nutrition Society. 2014. Reilly R, McNulty H, Pentieva K, Strain JJ, Ward M.Review

15. Fortification of Wheat and Maize Flour With Folic Acid for Population Health Outcomes.

The Cochrane Database of Systematic Reviews. 2019. Centeno Tablante E, Pachón H, Guetterman HM, Finkelstein JL.SR

16.Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement. The Journal of the American Medical Association. 2023. US Preventive Services Task Force, Barry MJ, Nicholson WK, et al.Guideline

17. Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders.Pharmacopsychiatry. 2022. Maruf AA, Poweleit EA, Brown LC, Strawn JR, Bousman CA.SR

18. The Role of Folate and MTHFR Polymorphisms in the Treatment of Depression. Alternative Therapies in Health and Medicine. 2021. Stengler M.